10.1161/CIRCHEARTFAILURE.112.970061Circulation: Heart Failure55571-57

Anand, I.S.

Carson, P.E.

Kitzman, D.W.

Komajda, M.

Kuskowski, M.

Lam, C.S.P.

Massie, B.M.

McKelvie, R.S.

McMurray, J.J.

Rector, T.S.

Zile, M.R.

PubMed

Background—There are few sex-specific outcome data in heart failure with preserved ejection fraction.



Methods and Results—We assessed sex differences in baseline characteristics and outcomes among 4128 patients with heart failure with preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Women (n=2491) with heart failure with preserved ejection fraction were ≈1 year older (72±7 years versus 71±7 years) and more likely to be obese (46% versus 35%) and have chronic kidney disease (34% versus 26%) and hypertension (91% versus 85%) than men but less likely to have an ischemic cause (19% versus 34%), atrial fibrillation (27% versus 33%), or chronic obstructive pulmonary disease (8% versus 13%) (all P&#60;0.001). During a mean of 49.5 months, there were 881 deaths (447 in women, 434 in men; risk ratio, 0.64; 95% CI, 0.56–0.74) and 5776 hospitalizations (3239 in women, 2537 in men; risk ratio, 0.80; 95% CI, 0.76–0.84). Women had lower risk of all-cause events (deaths and hospitalizations), even after adjusting for baseline characteristics (adjusted hazards ratio, 0.81; 95% CI, 0.73–0.89). However, the sex-related difference in risk of all-cause events was modified in the presence or absence of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class symptoms.



Conclusions—In patients with typical heart failure with preserved ejection fraction, there were prominent sex differences in baseline characteristics and outcomes. Women had better overall prognosis, although the presence of 4 common baseline characteristics seemed to moderate this finding.</p

Lam, C. S. P.

Carson, P. E.

Anand, I. S.

Rector, T. S.

McKelvie, R. S.

McMurray, J.J.V.

Zile, M. R.

Massie, B. M.

Kitzman, D. W.

Enlighten: Publications

Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: the irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial


            Background—
            There are few sex-specific outcome data in heart failure with preserved ejection fraction.
          
          
            Methods and Results—
            
              We assessed sex differences in baseline characteristics and outcomes among 4128 patients with heart failure with preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Women (n=2491) with heart failure with preserved ejection fraction were ≈1 year older (72±7 years versus 71±7 years) and more likely to be obese (46% versus 35%) and have chronic kidney disease (34% versus 26%) and hypertension (91% versus 85%) than men but less likely to have an ischemic cause (19% versus 34%), atrial fibrillation (27% versus 33%), or chronic obstructive pulmonary disease (8% versus 13%) (all
              P
              &lt;0.001). During a mean of 49.5 months, there were 881 deaths (447 in women, 434 in men; risk ratio, 0.64; 95% CI, 0.56–0.74) and 5776 hospitalizations (3239 in women, 2537 in men; risk ratio, 0.80; 95% CI, 0.76–0.84). Women had lower risk of all-cause events (deaths and hospitalizations), even after adjusting for baseline characteristics (adjusted hazards ratio, 0.81; 95% CI, 0.73–0.89). However, the sex-related difference in risk of all-cause events was modified in the presence or absence of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class symptoms.
            
          
          
            Conclusions—
            In patients with typical heart failure with preserved ejection fraction, there were prominent sex differences in baseline characteristics and outcomes. Women had better overall prognosis, although the presence of 4 common baseline characteristics seemed to moderate this finding.
          
          
            Clinical Trial Registration—
            
              URL:
              http://www.clinicaltrials.gov
              . Unique identifier: NCT000095238.
            
          </jats:sec

Carolyn S.P. Lam

Peter E. Carson

Inder S. Anand

Thomas S. Rector

Michael Kuskowski

Michel Komajda

Robert S. McKelvie

John J. McMurray

Michael R. Zile

Barry M. Massie

Dalane W. Kitzman

Crossref

Circulation Heart Failure

Sex Differences in Clinical Characteristics and Outcomes in Elderly Patients With Heart Failure and Preserved Ejection Fraction

There are few sex-specific outcome data in heart failure with preserved ejection fraction

Lam, Carolyn S. P.

Carson, Peter E.

Anand, Inder S.

Rector, Thomas S.

Kuskowski, Michael

Komajda, Michel

McKelvie, Robert

McMurray, John

Zile, Michael R.

Massie, Barry M.

Kitzman, Dalane W.

ACU Research Bank

Sex differences in clinical characteristics and outcomes in elderly patients with heart failure and preserved ejection fraction: The irbesartan in heart failure with preserved ejection fraction (I-PRESERVE) trial

&lt;p&gt;Background—There are few sex-specific outcome data in heart failure with preserved ejection fraction.&lt;/p&gt;



&lt;p&gt;Methods and Results—We assessed sex differences in baseline characteristics and outcomes among 4128 patients with heart failure with preserved ejection fraction in the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Women (n=2491) with heart failure with preserved ejection fraction were ≈1 year older (72±7 years versus 71±7 years) and more likely to be obese (46% versus 35%) and have chronic kidney disease (34% versus 26%) and hypertension (91% versus 85%) than men but less likely to have an ischemic cause (19% versus 34%), atrial fibrillation (27% versus 33%), or chronic obstructive pulmonary disease (8% versus 13%) (all P&#60;0.001). During a mean of 49.5 months, there were 881 deaths (447 in women, 434 in men; risk ratio, 0.64; 95% CI, 0.56–0.74) and 5776 hospitalizations (3239 in women, 2537 in men; risk ratio, 0.80; 95% CI, 0.76–0.84). Women had lower risk of all-cause events (deaths and hospitalizations), even after adjusting for baseline characteristics (adjusted hazards ratio, 0.81; 95% CI, 0.73–0.89). However, the sex-related difference in risk of all-cause events was modified in the presence or absence of atrial fibrillation, renal dysfunction, stable angina pectoris, or advanced New York Heart Association class symptoms.&lt;/p&gt;



&lt;p&gt;Conclusions—In patients with typical heart failure with preserved ejection fraction, there were prominent sex differences in baseline characteristics and outcomes. Women had better overall prognosis, although the presence of 4 common baseline characteristics seemed to moderate this finding.&lt;/p&gt

Enlighten

\ua9 2017 IUMS. Eleven actinobacterial strains were isolated from a rock sample collected in the Atacama Desert. Molecular typing by BOX-PCR divided the strains into three clusters and showed that, although very similar, they were not clones. Three strains, ATK01, ATK03T and ATK17, each representing one of the defined BOX clusters, were chosen for further characterization. Phylogenetic analysis indicated that the strains were related to the genus Pseudonocardia and were recovered in a cluster together with Pseudonocardia bannensis YIM 63101T and Pseudonocardia xinjiangensis AS 4.1538T. Chemotaxonomic analyses confirmed their affiliation to the genus Pseudonocardia but differences were found between the new strains and their closest phylogenetic relatives. Physiological and fatty acid analyses also revealed differences between these strains and their phylogenetic neighbours supporting their status as a distinct species. Based on the overall data, it is proposed that strains ATK01, ATK03T and ATK17 represent a novel species of the genus Pseudonocardia for which the name Pseudonocardia nigra sp. nov. is proposed (type strain ATK03T=DSM 104088T=CECT 9183T)

<em>Pseudonocardia nigra</em> sp. nov., isolated from Atacama Desert rock

Abstract

Similar works

Full text

Available Versions

Enlighten: Publications

Crossref

ACU Research Bank

Enlighten

Newcastle University E-Prints